A - Human Necessities – 61 – K
Patent
A - Human Necessities
61
K
A61K 39/395 (2006.01) G01N 33/574 (2006.01)
Patent
CA 2644148
A method for determining whether a patient in need thereof will respond to anti-VEGF antibody based chemotherapy by screening a suitable cell or tissue sample isolated from the patient for at least one genomic polymorphism or genotype selected from (i) IL 8( -251); (ii) VEGF(936); or (iii) AM (3' CA repeats), wherein the patient is suitably treated if the corresponding genotype is (i) (T/T) for IL-8(-251); (ii) (T/T or C/T) for VEGF(936); or (iii) at least one AM allele having 14 or more 3'CA repeats.
La présente invention concerne un procédé permettant de savoir si un patient concerné réagira à une chimiothérapie à base d'anticorps anti-VEGF. Ce procédé consiste, dans un échantillon cellulaire ou tissulaire approprié prélevé chez le patient, en une recherche systématique d'au moins un polymorphisme génomique ou d'un génotype choisi parmi les (i) IL 8( -251); (ii) VEGF(936); ou (iii) AM (répétitions de 3'CA), le patient étant correctement traité si le génotype correspondant est (i) (T/T) pour IL-8(-251); (ii) (T/T ou C/T) pour VEGF(936); ou (iii) au moins un allèle d'AM comportant au moins 14 répétitions de 3'CA.
Smart & Biggar
University Of Southern California
LandOfFree
Angiogenesis pathway gene polymorphisms for therapy selection does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Angiogenesis pathway gene polymorphisms for therapy selection, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Angiogenesis pathway gene polymorphisms for therapy selection will most certainly appreciate the feedback.
Profile ID: LFCA-PAI-O-1701521